BMRN
$87.46
Biomarin Pharmaceut
$.62
.71%
BMRN
Earnings Whisper ®
N/A
1st Quarter March 2017
Consensus:  ($0.31)
Revenue:  N/A
Thursday
May 25
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Thursday, February 23, 2017

What do you expect when BMRN reports earnings?
Beat
Meet
Miss

Where is BMRN's stock price going from here?
Up
Flat
Down
Stock chart of BMRN
Analysts
Summary of analysts' recommendations for BMRN
Score
Grade
Pivots
Resistance
$88.81
$88.35
$87.60

$87.14

Support
$86.39
$85.93
$85.18
Tweet
Growth
Description
BioMarin Pharmaceutical Inc. is a developer of carbohydrate enzyme therapies for debilitating, life-threatening, chronic genetic disorders and other diseases and conditions. The company completed a six-month evaluation of patients being treated with BioMarin's lead product, BM101, for the treatment of mucopolysaccharidosis-I, or MPS-I. Patients were treated with BM101 as part of a pivotal clinical trial completed to determine the safety and efficacy of the drug in humans.
Peers
Eli LillyJohnson & JohnsonRegeneron PharmaceuticalsVertex PharmaceuticalsCelgeneEndo International plcPfizerBristol-Myers SquibbInterCeptMerck & Co.